Cordis (medical)

From Wikipedia, the free encyclopedia
Cordis (a Cardinal Health Company)
Founded1957 (as The Medical Development Corporation)
FounderDr. William P. Murphy Jr.
HeadquartersSanta Clara, California, U.S.
Area served
Worldwide
ProductsMedical devices
WebsiteCordis.com

Cordis (a Cardinal Health company) develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.

Cordis was founded in 1959 in Miami, Florida and currently operates in North America, Europe, the Middle East, Africa, Asia-Pacific and Latin America markets. The Cordis global headquarters are located in Baar, Switzerland. The headquarters also acts as a hub for Cordis' operations in Europe, Africa and the Middle East. The North American operations are based out of the San Francisco Bay area. The Asia-Pacific hub is located in Singapore, and the Latin American hub in Puerto Rico.[1]

History[]

The Medical Development Corporation was founded in 1957 in Miami, Florida, by Dr. William P. Murphy Jr. and focused on interventional vascular medicine and neuroscience.[1] In 1959, the company’s name changed to Cordis.[1]

In 1962, the first synchronous cardiac pacemaker co-developed by Cordis was implanted in a patient.[2] During the 1970s, Cordis introduced the first sheath introducers with hemostasis valves, designed to minimize blood loss during an angioplasty procedure.[citation needed] In the 1980s, Cordis launched a line of percutaneous transluminal coronary angioplasty (PTCA) guiding catheters.[citation needed]

In the 1990s, Cordis introduced the first PTCA balloon utilizing nylon balloon material.[citation needed] In 1994, Cordis received FDA-approval for the first bare-metal stent in the US, the PALMAZ-SCHATZ Balloon-Expandable Stent for coronary artery applications.[3][4] In 1996, Cordis joined the Johnson & Johnson Intervention Systems (JJIS).[1][5][6] In 1997, Cordis Corporation expanded into electrophysiology after Johnson & Johnson acquired Biosense Inc. and merged it with Cordis.[7] In 1998, Biosense Inc. merged with Webster Laboratories to form Biosense Webster, Inc.[citation needed]

In 2002, the CYPHER Sirolimus-eluting Coronary Stent, the first drug-eluting stent for patients with coronary heart disease was approved for use in the EU.[8] In 2010, EXOSEAL a vascular closure device with extravascular bio absorbable plug placement received CE-mark in Europe.[9] In 2013, Cordis launched the Smart Flex Self-Expanding Stent System, a self-expanding vascular stent.[10] In 2014, Cordis Corporation announced the launch of its INCRAFT AAA Stent Graft System (INCRAFT System), a device for use during endovascular aneurysm repair (EVAR) for patients suffering from infrarenal abdominal aortic aneurysms (AAA).[11][12]

In 2015, Cardinal Health acquired the Cordis business from Johnson & Johnson for $1.944 billion.[13][14]

On October 31, 2016 Cardinal Health announced several new strategic distribution agreements enabling Cordis, Cardinal Health’s interventional vascular business, to expand its product portfolio. These distribution agreements were related to coronary stents and percutaneous transluminal coronary angioplasty (PTCA) balloon catheters in Cordis’ portfolio of products that support the treatment of patients undergoing percutaneous coronary intervention.[15]

In 2017, Cordis received the CE Mark for its RAILWAY™ Sheathless Access System, which enables direct access to the radial artery with a guiding catheter and eliminates the need for an introducer sheath, reducing the size of the arterial puncture site.[16][17] On March 31, 2017 Cardinal Health announced two new strategic agreements that enabled Cordis, Cardinal Health’s interventional vascular business, to expand its cardiology product offering in China. These strategic agreements added new percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, manufactured both in China and internationally, to the Cordis’ portfolio.[18]

In March 2021, Cardinal announced plans to sell Cordis to private equity firm Hellman & Friedman for $1 billion. [19]

Product categories[]

Cardiology products[]

Endovascular products[]

References[]

  1. ^ Jump up to: a b c "Gateway City/Who's Here: Cordis plant in Miami Lakes produces high-tech cardiac catheter components for world market". 25 October 2015.
  2. ^ Jeffrey, Kirk (2003-04-01). Machines in Our Hearts: The Cardiac Pacemaker, the Implantable Defibrillator, and American Health Care. JHU Press. ISBN 978-0-8018-7616-5.
  3. ^ Scott (2007-05-24). "J&J Returns to Old-School Stents". Wall Street Journal. ISSN 0099-9660. Retrieved 2021-08-26.
  4. ^ "FDA Approves New Heart Stents". 22 December 1997.
  5. ^ "COMPANY NEWS;JOHNSON & JOHNSON WILL COMPLETE PURCHASE OF CORDIS". The New York Times. 23 January 1996. ISSN 0362-4331. Retrieved 2021-08-26.
  6. ^ STIEGHORST, TOM. "CORDIS APPROVES J&J MERGER". Sun-Sentinel.com. Retrieved 2021-08-26.
  7. ^ "Johnson & Johnson Buys Biosense For $400 Mln in Shares - Globes". en.globes.co.il (in Hebrew). 1997-09-29. Retrieved 2021-08-26.
  8. ^ "Cordis to Stop Making Cypher, Nevo Stents". www.medpagetoday.com. 2011-06-15. Retrieved 2021-08-26.
  9. ^ "Cordis's ExoSeal Receives CE Mark Approval". Endovascular Today. Retrieved 2021-08-26.
  10. ^ "Medtronic, J&J's Cordis headline EuroPCR 2013". FierceBiotech. Retrieved 2021-08-26.
  11. ^ "Cordis brings Incraft AAA stent graft to Europe and Canada". MassDevice. Retrieved 2021-08-26.
  12. ^ "Incraft low-profile endograft launched in Europe and Canada". Vascular News. 2014-09-09. Retrieved 2021-08-26.
  13. ^ "J&J confirms $1.9B sale of Cordis unit to Cardinal Health, ending months of speculation". FierceBiotech. Retrieved 2021-08-26.
  14. ^ "Cardinal Health to sell off its Cordis device division in $1B deal". FierceBiotech. Retrieved 2021-08-26.
  15. ^ "Cardiac Interventions Today - Cardinal Health Announces Strategic Distribution Agreements in International Markets". Cardiac Interventions Today. Retrieved 2017-06-22.
  16. ^ http://fyra.io. "Cordis Railway Sheathless Access System Approved in Europe". Cardiac Interventions Today. Retrieved 2021-08-26.
  17. ^ "Cordis Unveil New Interventional Cardiology Products | Medgadget". Retrieved 2021-08-26.
  18. ^ "Top Global Medical Device Companies - Medical Product Outsourcing". www.mpo-mag.com. Retrieved 2021-08-26.
  19. ^ "Cardinal Health to sell off its Cordis device division in $1B deal". FierceBiotech. Retrieved 2021-08-26.
Retrieved from ""